Patient characteristics. Two comparisons were made for the purposes of this inves- tigation: (1) patients with bacteriuria vs nonbacteriuria control subjects (Table 1), and (2) UTI vs ASB subjects (Table 2). All 296 study subjects were white. ■ Patients with bacteriuria vs control subjects —When com- pared with individuals from the nonbacteriuria control group ( Table 1), patients with bacteriuria (either UTI or ASB) were more often: ▫ female (84% vs 75%; OR, 1.84; 95% CI, 1.03-3.26) ▫ nursing home residents (OR, 1.74; 95% CI, 1.08-2.80) ▫ had a history of hypertension (OR, 1.81; 95% CI, 1.14-2.87) ▫ received bladder catheterization in the ED or on admission (OR, 1.72; 95% CI, 1.08-2.74) JAOA • Vol 109 • No 4 • April 2009 • 221 ■ Mean (SD) Age, y 83 (8) 82 (8) ... ■ Female 130 (84) 106 (75) 1.84 (1.03-3.26)† ■ Nursing Home Resident 68 (44) 47 (33) 1.74 (1.08-2.80)† ■ Medical History ▫ Cognitive impairment 47 (31) 38 (27) 1.20 (0.73-1.99) ▫ Cardiovascular health – Hypertension 93 (60) 65 (46) 1.81 (1.14-2.87)† – Stroke 30 (19) 34 (24) 0.77 (0.44-1.34) ▫ Pulmonary disease – Chronic obstructive pulmonary disease 33 (21) 36 (25) 0.80 (0.47-1.38) – Pneumonia 16 (10) 19 (13) 0.75 (0.37-1.52) ▫ Diabetes mellitus 45 (29) 34 (24) 1.31 (0.78-2.20) ▫ Falls 16 (10) 9 (6) 1.71 (0.73-4.01) ■ Hospital Care‡ ▫ Bladder catheter 78 (51) 53 (37) 1.72 (1.08-2.74)† ▫ Antibiotic treatment 92 (60) 67 (47) 1.66 (1.05-2.63) † – Levofloxacin treament 53 (58) 26 (39) 2.09 (1.10-3.96)† ■ Ischuria§ 5 (4) 11 (8) 0.44 (0.15-1.31) ■ Delirium 46 (30) 11 (8) 5.07 (2.51-10.27)† ■ Cardiovascular Health ▫ Atrial fibrillation 19 (12) 19 (13) 0.91 (0.46-1.80) ▫ Congestive heart failure 31 (20) 18 (13) 1.74 (0.92-3.27) ■ Pulmonary Disease 42 (27) 59 (42) 0.53 (0.32-0.86)† ▫ Pneumonia 23 (15) 32 (23) 0.60 (0.33-1.09) ■ Diabetes Mellitus With Hyperglycemia 32 (21) 27 (19) 1.12 (0.63-1.98) ■ Falls 26 (17) 20 (14) 1.24 (0.66-2.33) ▫ Fracture 8 (5) 12 (8) 0.59 (0.23-1.50) ▫ No fracture 18 (12) 8 (6) 2.22 (0.93-5.27) ■ Blood Test Results ▫ Serum urea nitrogen/ creatinine ratio, “20:1 79 (51) 68 (48) 1.15 (0.73-1.81) ▫ Electrolyte panel (imbalance) 51 (33) 58 (41) 0.72 (0.45-1.15) ▫ Serum albumin, <3.0 g/dL 54 (35) 37 (26) 1.53 (0.93-2.53) * Data are presented as No. (%) unless indicated otherwise. † Statistically significant difference (P<.05). ‡ Bladder catheterization was provided in the emergency department or on hospital admission; antibiotic treatment was dispensed in the emergency department. Subjects in the nonbacteriu...
Patient characteristics. A total of 299 patients (79%) participating in the GIPS-III trial underwent 2D TTE assessment, image quality was insufficient to determine LV mass in 9 subjects and to determine LV volumes in 38 subjects. CMR was performed in 275 patients (73%), image quality was insufficient to determine LV mass in 8 subjects and to determine LV volumes in 4 subjects. CMR and 2D TTE measurements were available in 259 patients (61%), of which LV mass measurements in both imaging modalities were available in 255 patients and LV volume measurements in 236 patients. In-hospital clinical, angiographic and biochemical characteristics, as well as medication at discharge, are presented in Table 1. Median infarct size was 7.2% (2.6, 13.7) of LV mass.
Patient characteristics. We examined 232 patients clinically-suspected of XXXX of whom we received samples for diagnostic testing between March 22th and November 26th 2021 (Table 1). Our cohort consisted of 111 females and 121 males with a median age of 62 (IQR: 53-68). Of the 232 XXXX suspected patients 112 (48%) were vaccinated with ChAdOx1 nCoV-19, 7 (3%) with Ad26.COV2.S, 34 (15%) with mRNA-1273, and 79 (34%) with BTN162b2. Patients were admitted, on average, 21 days after vaccination. Our cohort contained seven confirmed HIT-like XXXX patients (for patients’ de- scription: Table S1). All other patients tested negative in both the anti-PF4 IgG ELISA and FcγRIIa-dependent PIPAA or did not have both thrombocytopenia and thrombosis (for patients’ description: Table S2). Chapter 9 Median age (IQR) 62 (53-68) 62 (54-69) 60 (53-69) Female sex (no.(%)) 111 (48%) 24 (55%) 87 (46%) Male sex (no.(%)) 121 (53%) 20 (45%) 101 (54%) Vaccination Vaccine type (no.(%)) Adenoviral vector vaccines 119 (51%) 20 (45%) 99 (53%) ChAdOx1 nCoV-19 112 (48%) 19 (43%) 93 (50%) Ad26.COV2.S 7 (3%) 1 (2%) 6 (3%) mRNA vaccines 113 (49%) 24 (55%) 89 (47%) mRNA-1273 34 (15%) 7 (16%) 27 (14%) BTN162b2 79 (34%) 17 (39%) 62 (33%) Days between admission and vaccination Mean (IQR) 21 (8-28) 24 (9-29) 21 (8-28) Number of vaccination (no.(%)) First dose 37 (16%) 10 (23%) 31 (17%) Second dose 68 (29%) 15 (34%) 55 (29%) Third dose 2 (1%) - 2 (1%) No information on dose 125 (54%) 19 (43%) 100 (53%) 148 Thrombocytopenia (<100x109/L) 151 (65%) 34 (77%) 117 (62%) Median platelet count (IQR) 51 (18-99) 35 (8-63) 55 (21-108) No thrombocytopenia 55 (24%) 4 (9%) 51 (27%) No data on platelet count 26 (11%) 6 (14%) 20 (11%) Thrombosis 71 (31%) 7 (16%) 64 (34%) No thrombosis 129 (56%) 31 (71%) 98 (52%) No data on thrombosis available 32 (14%) 6 (14%) 26 (14%) Thrombocytopenia and thrombosis 32 (14%) 3 (7%) 29 (15%) Thrombocytopenia only 119 (51%) 31 (71%) 88 (47%) Thrombosis only 39 (17%) 4 (9%) 35 (19%) Neither thrombocytopenia nor thrombosis 19 (8%) 1 (2%) 18 (10%) No data on both thrombocytopenia and thrombosis 23 (10%) 5 (11%) 18 (10%) Anti-PF4 ELISA negative (OD < 1.0) 212 (91%) 42 (96%) 170 (90%) PIPAA negative 206 (97%) 38 (90%) 168 (99%) PIPAA positive 6 (3%) 4 (10%) 2 (1%) Anti-PF4 ELISA weak-positive (1.0 ≤ OD < 2.0) 7 (3%) 1 (2%) 6 (3%) PIPAA negative 6 (86%) 1 (100%) 5 (83%) PIPAA positive 1 (14%) - 1 (17%) Anti-PF4 ELISA positive (OD ≥ 2.0) 13 (6%) 1 (2%) 12 (6%) PIPAA negative 3 (23%) 1 (100%) 2 (17%) PIPAA positive...
Patient characteristics. A cohort of 3,513 DLBCL patients was identified, including 922 patients (26%) >80 years old at diagnosis. The mean and median ages at diagnosis in the sub-cohort of patients >80 years old were 85 and 84 years, respectively. The corresponding mean and median estimate for those ≤80 years of age was 73 years. Characteristics of patients in each age category are displayed in Table 1. Compared to patients ≤80 years old, those >80 years old were more likely to be female, widowed, live in a metropolitan area, have extranodal disease, and have poor performance status; patients >80 years old were less likely to have late stage disease and to live in a census tract with >25% of residents completing high school only (all p<0.05).
Patient characteristics. Between 2010 and 2012, a total of 12,529 patients received at least one platelet transfusion in Denmark. Of these, 826 patients were excluded based on age at time of transfusion and 1,927 patients were excluded as they only received a transfusion in a hospital that accounted for fewer than 1000 platelet transfusions in the study period. The final cohort consisted of 9,776 patients, more men than women (62.3% versus 37.7%), with an average age of 64.1 years (table 1). During the study period, these patients received 66,101 platelet transfusions, of which 22,240 units (33.6%) were stored for six or seven days. This relatively large proportion of old platelet concentrates is a consequence of the first-in-first-out policy. Forty-nine percent of all platelet concentrates were transfused to patients with a hematological malignancy, 15.6% to patients with trauma or xxxxx, and 8.6% to patients who underwent cardiothoracic surgery. The distribution of diagnoses was similar among the storage time categories. Information about blood group of the product was missing for 11,156 products, but this was equally distributed among the storage time categories. The proportion of rhesus D negative products increased with increasing storage time (Table 2). Patients, n 9,776 Male, n (%) 6,088 (62.3) Age, n (%) 18-49 years 1,533 (15.7) 50-74 years 6,011 (61.5) ≥75 year 2,232 (22.8) Mean (SD) age in years 64.1 (14.6) Median (IQR) number of transfused platelet concentrates 2 (1-6) Median (IQR) number of transfused red blood cell concentrates 12 (5-24) Median (IQR) number of transfused plasma products 2 (0-8) Number of platelet concentrates (%)* 34,722 (52.5) 22,240 (33.6) 66,101 (100) Male, n(%)† 21,628 (62.3) 14,151 (63.6) 41692 (63.1) Mean (SD) age in years† 60.3 (14.9) 60.0 (15.1) 60.2 (14.9) Median (IQR) number of prior 32 (9-79) 33 (9-83) 34 (10-84) transfusions all products Main indication Hematology 17,029 (49.0) 10,681 (48.0) 32,547 (49.2) Cardiothoracic surgery 3,017 (8.7) 1,914 (8.6) 5,657 (8.6) Trauma and xxxxx 5,407 (15.6) 3,429 (15.4) 10,319 (15.6) Bleeding 1,177 (3.4) 675 (3.0) 2,106 (3.2) Unknown 8,092 (23.3) 5,541 (25.0) 15,472 (23.4) Donor ABO blood group, n (%) A 13,958 (40.2) 8,019 (36.1) 22,377 (33.9) B 1,551 (4.5) 510 (2.3) 2,084 (3.2) AB 9 (0.03) 1 (0.0) 15 (0.0) O 16,736 (48.2) 12,216 (54.9) 30,469 (46.1) Rhesus antigen positivity, n (%) 26,949 (77.6) 14,094 (63.4) 42,065 (63.6) Missing blood group, n (%) 2,468 (7.1) 1,494 (6.7) 11,156 (16.9)
Patient characteristics. Characteristics Number (percentage)
Patient characteristics. ECG analysis was performed by LEADS (Leiden ECG Analysis and Decompo- sition Software), our MATLAB (The MathWorks, Natick, USA) program for re- search oriented ECG analysis. LEADS first computed an averaged beat in order to minimize noise. In this averaged beat, the beginning and end of the QRS complex were automatically detected. An observer, who was blinded to the patient data, cor- rected this interval if necessary. LEADS identified the apex and end of the T wave in each ECG lead. The end of the T wave was set at the point where the tangent to the steepest portion of the terminal part of the T wave crossed the isoelectric line. Subsequently, LEADS searched backward for the apex of the T wave, defined as the point of the T wave with the highest amplitude. Finally, LEADS calculated a num- ber of ECG indices proposed to assess dispersion of the repolarization: the Tapex- end interval8, QT interval12, T-wave amplitude13, T-wave surface area14 and T-wave complexity15. QT and Tapex-end intervals were corrected for heart rate by the Bazett formula16. T-wave complexity was calculated by means of singular value decomposi- tion of the T wave15;17. The higher, more complex, singular values 2 to 8 were divided by the first, most simple component to quantify T-wave complexity. Additionally, LEADS constructed the vectorcardiogram by using the inverse Dower matrix18;19 and calculated the spatial angle between the QRS and T axes.
Patient characteristics. Forty-seven patients (53.2% female, median age 62 years, range 22-74 years) and 47 healthy controls (76.6% female, median age 54 years, range 24-66 years) were vaccinated with the seasonal influenza vaccine from October to December 2016. Healthy controls were significantly younger (p=0.001) and were more frequently female (p=0.02) than the MG group. In the MG group, 23 patients randomly received a placebo injection followed by flu vaccination 4 weeks later. Baseline characteristics did not differ between the two MG patients groups that either received first the flu vaccination or the placebo vaccination. The MG group consisted of 29 patients with (IM+) and 18 without (IM-) immunosuppressive medication. The IM+ group was significantly older (p<0.01) than the IM- group and contained more female patients (p=0.04). Disease duration and whether a patient underwent a thymectomy in the past was not significantly different between IM- and IM+ groups (p=0.4 and p=0.16, respectively). Baseline characteristics are given in Table 1.
Patient characteristics. Patient Characteristics (n=863) Male (%) 646 (74.9) Age (years) 61 ± 13 BMI (kg/m2) 28.4 (24.9-41.1) BMI ≥30 kg/m2 (%) 374 (43.3) Region of residency (%) 1 265 (30.7) 2 253 (29.3) 3 185 (21.4) 4 160 (18.5) Risk factors for coronary diseases (%) Smoking 462 (53.5) Hypertension 307 (35.6) Hyperlipidemia 167 (19.4) Family History 358 (41.5) Diabetes Mellitus 108 (12.5) Prior Myocardial Infarction 90 (10.4) Median time intervals in minutes (IQR) Onset Symptoms - Arrival at Cath-Lab 150 (101-280) Door - Arrival at Cath-Lab 23 (13-42) Onset Symptoms – Alert of Emergency Services 61 (25-158) Alert of Emergency Services – Arrival at Hospital 48 (40-60) Hospitalization Days hospitalized (median [IQR]) 2 (2-3)
